Chang emphasizes a medically precise, patient-first approach to Vitamin B12 therapy
Wolffenbuttel BHR, McCaddon A, Ahmadi KR, Green R Food and nutrition bulletin 2024
Patient-centred strategies must identify patients tumour, current and planned conventional therapies (chemotherapy, endocrine therapy, targeted therapy and immunotherapy), comorbidities, organ function, nutrition profile, dietary habits and existing medication or supplement use since these factors critically impact both the efficacy and safety of supplementary approaches (236)
To date, PARP inhibitors, including niraparib, rucaparib and olaparib have been approved by US-FDA to treat cancers, including prostate cancer, breast cancer and ovarian cancer, through disrupting DNA repair and replication pathways